August 2017

New Product - Obizur

Obizur (susoctocog alfa (bhk)) is a recombinant analogue of porcine coagulation factor VIII, with the B domain deleted. Patients with acquired haemophilia A have normal factor VIII genes but develop autoantibodies against their own factor VIII (i.e. inhibitors), creating a functional deficiency of this procoagulant protein. Obizur is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A. Safety and efficacy of Obizur have not been established in patients with baseline antiporcine factor VIII inhibitor titre greater than 20 BU. Obizur is not indicated for the treatment of congenital haemophilia A or von Willebrand disease. Obizur 500 unit single use vials are available in packs of 1, 5 and 10.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au